MIRA Pharmaceuticals, Inc. (MIRA)
NASDAQ: MIRA · Real-Time Price · USD
1.245
+0.035 (2.89%)
At close: Jun 27, 2025, 4:00 PM
1.250
+0.005 (0.40%)
After-hours: Jun 27, 2025, 7:25 PM EDT
MIRA Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts that cover MIRA Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $14, which forecasts a 1024.5% increase in the stock price over the next year. The lowest target is $11 and the highest is $17.
Price Target: $14 (+1024.5%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 30, 2024.
Analyst Ratings
The average analyst rating for MIRA Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Apr '25 | May '25 | Jun '25 |
---|---|---|---|
Strong Buy | 2 | 2 | 2 |
Buy | 0 | 0 | 0 |
Hold | 0 | 0 | 0 |
Sell | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 |
Total | 2 | 2 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $17 | Strong Buy | Initiates | $17 | +1,265.46% | Sep 30, 2024 |
Ascendiant Capital | Ascendiant Capital | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +783.53% | Aug 5, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.45
from -0.51
EPS Next Year
-0.33
from -0.45
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 |
---|---|---|
High | n/a | n/a |
Avg | n/a | n/a |
Low | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
EPS Forecast
EPS | 2025 | 2026 |
---|---|---|
High | -0.46 | -0.25 |
Avg | -0.45 | -0.33 |
Low | -0.43 | -0.40 |
EPS Growth
EPS Growth | 2025 | 2026 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.